Cholestasis Causes Discrepancy in HDL-Cholesterol Levels Measured Using Various Methods

Sollip Kim; Sail Chun; Woochang Lee; Ghi-Su Kim; Won-Ki Min

doi:10.3343/lmo.2012.2.3.174

Journal List > Lab Med Online > v.2(3) > 1057165

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Kim, Chun, Lee, Kim, and Min: Cholestasis Causes Discrepancy in HDL-Cholesterol Levels Measured Using Various Methods

Case Discussion

Clinical Chemistry

Laboratory Medicine Online

Laboratory Medicine Online 2012; 2(3): 174-178.

Published online: 1 July 2012

DOI: https://doi.org/10.3343/lmo.2012.2.3.174

Cholestasis Causes Discrepancy in HDL-Cholesterol Levels Measured Using Various Methods

Sollip Kim, M.D.¹, Sail Chun, M.D.², Woochang Lee, M.D.², Ghi-Su Kim, M.D.³, Won-Ki Min, M.D.²

¹Department of Laboratory Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.

²Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea.

³Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea.

Corresponding author: Won-Ki Min, M.D. Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Pungnap 2-dong, Songpa-gu, Seoul 138-736, Korea. Tel: +82-2-3010-4503, Fax: +82-2-478-0884, wkmin@amc.seoul.kr

Received 7 May 2012 Revised 11 May 2012 Accepted 14 May 2012

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Herein, we report a case in which cholestasis caused discrepancy in high-density lipoprotein (HDL)-cholesterol levels measured using various methods. The discrepancy in HDL-cholesterol level originated from the abnormal increase in the level of an unusual lipoprotein, apo E-rich HDL, in the patient's serum. An abnormal slow alpha-migrating lipoprotein was observed on agarose gel electrophoresis, and an abnormal large-sized HDL was observed in a lipoprotein subfraction study. The level of apolipoprotein E was elevated.

Keywords: HDL-Cholesterol, Cholestasis, Discrepancy

Figures and Tables

Fig. 1

Result of lipoprotein electrophoresis of the patient.

Fig. 2

LDL subfraction test result of the patient.

The red circle shows the large-sized abnormal HDL fraction (b).

Table 1

Laboratory data of the patient

^*We performed chemical tests by using the Kyowa reagent in the instrument Toshiba 200FR.

Abbreviations: NA, not available; EP, electrophoresis.

Table 2

Reexamination results of lipid profile in the patient

Abbreviation: NT, not tested.

Notes

This article is available from http://www.labmedonline.org

References

1. Min WK, Park H, Jun KR, Chun S, Lee W. Factors affecting the difference between the low-density lipoprotein cholesterol concentrations measured directly and calculated using the friedewald formula. J Lab Med Qual Assur. 2008. 30:233–235.

2. Hur M, Kim CS, Park MJ, Kwak I, Lee KM. Analysis of low-density lipoprotein cholesterol by homogenous assay in comparison with friedewald formula. Korean J Lab Med. 2003. 23:104–108.

3. Remaley AT, Rifai N, Warnick R. Burtis CA, Ashwood ER, editors. Lipids, lipoproteins, apolipoproteins, and other cardiovascular risk factors. Tietz textbook of clinical chemistry and molecular diagnostics. 2012. 5th ed. St. Louis: Elsevier;731–805.

4. Remaley AT, Warnick GR. HDL-C. The changing testing paradigm part 1. Clinical Laboratory News. 2007. Washington: American Association for Clinical Chemistry.

5. Clifton PM, Barter PJ, Mackinnon AM. High density lipoprotein particle size distribution in subjects with obstructive jaundice. J Lipid Res. 1988. 29:121–135.

6. Coulhon MP, Tallet F, Yonger J, Agneray J, Raichvarg D. Changes in human high density lipoproteins in patients with extra-hepatic biliary obstruction. Clin Chim Acta. 1985. 145:163–172.

7. Yamashita S, Sprecher DL, Sakai N, Matsuzawa Y, Tarui S, Hui DY. Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency. J Clin Invest. 1990. 86:688–695.

8. Chiba H, Osaka T, Iwasaki N, Suzuki H, Akizawa K, Fujisawa S, et al. Spurious elevation of serum high-density lipoprotein cholesterol in patients with cholestatic liver diseases. Biochem Med Metab Biol. 1991. 46:329–343.

9. Tallet F, Vasson MP, Couderc R, Lefevre G, Raichvarg D. Characterization of lipoproteins during human cholestasis. Clin Chim Acta. 1996. 244:1–15.

10. Black DD. Chronic cholestasis and dyslipidemia: what is the cardiovascular risk? J Pediatr. 2005. 146:306–307.

11. Werner A, Kuipers F, Verkade HJ. Fat absorption and lipid metabolism in cholestasis. Madame Curie Bioscience Database [Internet]. 2000. Austin (TX): Landes Bioscience.

12. Claudel T, Sturm E, Duez H, Torra IP, Sirvent A, Kosykh V, et al. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest. 2002. 109:961–971.

13. Lund-Katz S, Phillips MC. High density lipoprotein structure-function and role in reverse cholesterol transport. Subcell Biochem. 2010. 51:183–227.

14. Krauss RM. Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol. 2010. 21:305–311.

15. Hopkins PC, Huang Y, McGuire JG, Pitas RE. Evidence for differential effects of apoE3 and apoE4 on HDL metabolism. J Lipid Res. 2002. 43:1881–1889.

TOOLS

Similar articles